Article Text

PDF

Clinical application of autologous technetium-99m-labelled eosinophils to detect focal eosinophilic inflammation in the lung
  1. Chrystalla Loutsios1,
  2. Neda Farahi1,
  3. Rosalind Simmonds1,
  4. Ian Cullum2,
  5. Daniel Gillett2,
  6. Chandra Solanki2,
  7. Kishor Solanki2,
  8. John Buscombe2,
  9. Alison M Condliffe1,
  10. A Mike Peters3,
  11. Edwin R Chilvers1
  1. 1Division of Respiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK
  2. 2Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge, UK
  3. 3Clinical Imaging Sciences Centre, Brighton and Sussex Medical School, Brighton, UK
  1. Correspondence to Professor Edwin R Chilvers, Division of Respiratory Medicine, Department of Medicine, University of Cambridge, Box 157, Level 5, Addenbrooke's and Papworth Hospitals, Cambridge CB2 0QQ, UK; erc24{at}cam.ac.uk

Abstract

Abstract The detection of focal eosinophilic inflammation by non-invasive means may aid the diagnosis and follow-up of a variety of pulmonary pathologies. All current methods of detection involve invasive sampling, which may be contraindicated or too high-risk to be performed safely. The use of injected autologous technetium-99m (Tc-99m)-labelled eosinophils coupled to single-photon emission computed tomography (SPECT) has been demonstrated to localise eosinophilic inflammation in the lungs of a patient with antineutrophil cytoplasmic antibody-positive vasculitis. Here, we report on the utility of this technique to detect active eosinophilic inflammation in a patient with focal lung inflammation where a biopsy was contraindicated.

  • Eosinophil Biology
  • Imaging/CT MRI etc
  • Pulmonary eosinophilia

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Statistics from Altmetric.com

To the editor

Our patient, a 69-year old with a background of asthma, presented with a 14-month history of increasing wheeze and cough, followed by acute deterioration with breathlessness, weight loss and anorexia. On admission, he was haemodynamically unstable and severely hypoxaemic. Thoracic computed tomography (CT) revealed a right-sided pneumothorax with peripheral ground glass opacities and consolidation throughout the left lung, raising the possibility of chronic eosinophilic pneumonia. Tests revealed marked blood eosinophilia of 2.3×109/L and an elevated immunoglobulin E (IgE) at 910 kU/L; his rheumatoid factor, antinuclear antibody and antineutrophil cytoplasmic antibody were negative. His IgG4 was elevated at 6.54 g/L (normal range (NR) 0–1.3 g/L), suggestive of possible IgG4-related disease. His pneumothorax was successfully aspirated and he was given oxygen and empirical broad-spectrum antibiotics. As he was initially too unwell to undergo bronchoscopy, a Tc-99m-eosinophil-single-photon emission computed tomography (SPECT/CT) scan was undertaken, as this novel technique has been demonstrated previously to localise biopsy-proven pulmonary eosinophilic inflammation.1

Tc-99m-labelled autologous eosinophils were prepared using anti-CD16 microbeads as described previously.2 Tc-99m-eosinophils (192 MBq) were injected and dynamic gamma camera imaging commenced, followed by SPECT; a single low-dose CT to enable anatomical alignment was performed. Within 5 min, uptake of labelled cells was visible on planar images of his left lung (see figure 1A) in addition to the expected physiological uptake in the liver, spleen and bone marrow. Increased activity was further demonstrated in his left lung on cross-sectional SPECT (see figure 1B). Coronal, sagittal and transaxial SPECT/CT images indicated focal uptake of radiolabelled eosinophils in regions of the lung corresponding to abnormal areas on CT (see figure 1C–E). These results provided evidence of pulmonary eosinophilic inflammation and supported the early use of high-dose oral corticosteroids, which led to rapid clinical improvement. The patient's serum on the day of the SPECT was analysed using a multiplex cytokine and chemokine array (MSD MULTI-SPOT Array System) and showed raised levels (pg/mL) of interleukin (IL)-5, 2.2 (NR <0.62 pg/mL), IL-15, 5.6 (NR <3.01 pg/mL); eotaxin, 428 (NR <145 pg/mL), eotaxin 3, 130 (NR <8.73 pg/mL) and monocyte chemotactic protein-4 (MCP-4), 358 (NR <117 pg/mL).

Figure 1

(A) Reframed composite image of the first 5 min of the dynamic planar gamma camera scan. Increased 99m-Tc-eosinophil uptake is visible in the left lung. LL, left lung; L, liver; S, spleen. (B) Transaxial single-photon emission computed tomography (SPECT) image showing increased activity in the vertebra and left lung (LL). L, left; R, right; V, vertebra. (C–E) Coronal, sagittal and transaxial sections through the lung. SPECT/CT (lower panel) demonstrating focal 99m-Tc-eosinophil uptake in areas of abnormality in the CT (upper panel), (white arrows). (F) Raw gamma counter results showing increased counts in the bronchoalveolar lavage fluid (BALF) compared with the BAL supernatant and natural background counts.

Within 48 h, his oxygenation had improved, allowing bronchoscopy. The bronchoalveolar lavage fluid (BALF) obtained had double the radioactive counts per minute (cpm) (19.5 cpm/mL) than the control fluid (phosphate-buffered saline) (9.3 cpm/mL) (see figure 1F). Counts in the supernatant (9 cpm/mL) after centrifugation were identical to the control, demonstrating that the radioactivity detected in the BALF was cell associated.

The patient made a rapid and complete recovery following treatment with oral prednisolone.

This case demonstrates the ability of Tc-99m-eosinophil-SPECT/CT to confirm pulmonary eosinophilic inflammation in patients where acquisition of BALF or lung biopsy was contraindicated. This methodology has the potential to be used clinically alongside or as a non-invasive alternative to conventional methods of detecting parenchymal eosinophilia. It may also aid in the translation of novel therapeutics by providing a platform to test their efficacy in reducing tissue eosinophilia.

Acknowledgments

The authors thank all the staff at the Department of Nuclear Medicine at Addenbrooke's Hospital and the Wellcome Trust Clinical Research Facility, Cambridge; Cambridge Biomedical Research Centre Core Biochemistry Assay Laboratory; and the National Institute for Health Research, through the Comprehensive Clinical Research Network.

References

View Abstract

Footnotes

  • CL and NF are joint first authors.

  • Funding This work was supported by Asthma-UK (08/11), the Medical Research Council (grant number MR/J00345X/1), the Wellcome Trust (grant number 098351/Z/12/Z), and Cambridge NIHR Biomedical Research Centre.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval Written informed consent was obtained in accordance with the Declaration of Helsinki. The study was approved by Cambridgeshire Research Ethics Committee (09/H0308/119) and the Administration of Radioactive Substances Advisory Committee of the UK (83/3130/25000).

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.